CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 161 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,613,760 | +118.8% | 313,000 | +186.1% | 0.13% | +75.0% |
| Q1 2023 | $3,936,212 | -56.3% | 109,400 | -45.8% | 0.08% | -45.7% |
| Q4 2022 | $8,998,683 | +54.0% | 201,900 | -2.9% | 0.14% | +75.0% |
| Q3 2022 | $5,842,000 | -81.5% | 207,844 | -82.3% | 0.08% | -81.6% |
| Q2 2022 | $31,589,000 | +83.6% | 1,171,700 | +131.9% | 0.44% | +110.1% |
| Q1 2022 | $17,207,000 | -16.1% | 505,200 | -4.8% | 0.21% | -9.6% |
| Q4 2021 | $20,509,000 | +63.0% | 530,700 | +127.8% | 0.23% | +59.0% |
| Q3 2021 | $12,579,000 | +230.5% | 233,000 | +104.7% | 0.14% | +188.0% |
| Q2 2021 | $3,806,000 | +116.4% | 113,800 | +13.3% | 0.05% | +25.0% |
| Q4 2020 | $1,759,000 | – | 100,400 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |